Eliminating tuberculosis is possible. Yet, this preventable and largely treatable infectious disease takes the lives of 1.5 million people every year. The COVID-19 pandemic has jeopardized years of painstaking progress on eliminating the disease. The time for paradigm shift and a renewed focus on TB is now. Join Devex and Stop TB Partnership in the #TalkingTB series, where we'll explore how to get efforts to end TB back on track — from hearing about the realities of living with the disease, to how technology could be leveraged to help, and what lessons can be learned from other diseases to tackle tuberculosis.

Themes

Dynamics of a disease: Characteristics and challenges

Dynamics of a disease: Characteristics and challenges

Read more
Living with TB: Community experiences and solutions

Living with TB: Community experiences and solutions

Read more
Leveraging technology: Scaling up tools for impact

Leveraging technology: Scaling up tools for impact

Read more
Gaining momentum: Looking forward, learning from past successes

Gaining momentum: Looking forward, learning from past successes

Read more
Stats

More news on TB

4 questions for John Green, the 'tuberculosis hater'

4 questions for John Green, the 'tuberculosis hater'


By Jenny Lei Ravelo

John Green is known for writing best-selling young adult fiction novels. But recently, he's been lending his star power to another cause: tuberculosis.

WHO's Jeremy Farrar says he's optimistic about tuberculosis. Here’s why

WHO's Jeremy Farrar says he's optimistic about tuberculosis. Here’s why


By Jenny Lei Ravelo

The world's only licensed vaccine for tuberculosis is more than a century old and is not effective in preventing TB disease among adults. But there's hope with the current pipeline of vaccines.

Study: Common antibiotic reduces risk of drug-resistant tuberculosis

Study: Common antibiotic reduces risk of drug-resistant tuberculosis


By Jenny Lei Ravelo

MDR-TB is more challenging to treat, and medications can produce many side effects. However, there are currently no preventive treatments for MDR-TB for adults or children.

The harsh reality of multidrug resistant TB in children

The harsh reality of multidrug resistant TB in children


By Jenny Lei Ravelo

Only about 12%-16% of children and young adolescents with MDR-TB or rifampicin-resistant TB were diagnosed and treated in 2022. Diagnosing them is hard, and the treatment course is lengthy and side-effect-prone.

WHO recommends shorter treatment for drug-resistant TB

WHO recommends shorter treatment for drug-resistant TB


By Jenny Lei Ravelo

WHO has previously recommended shorter treatment regimens for drug-resistant TB, but only under operational research conditions, meaning only very few countries can use it — this new recommendation looks to change that.

The Global Fund embraces integration of chronic diseases

The Global Fund embraces integration of chronic diseases


By Andrew Green

Links between AIDS and TB and noncommunicable diseases have driven calls for the Global Fund to expand its focus to offer more funding for services that integrate NCDs such as cardiovascular disease and diabetes.

Yes! We Will End TB!

Yes! We Will End TB!


By Prof. Julio RAKOTONIRINA, Director of Health and Humanitarian Affairs, African Union Commission

Active case-finding breaks the chain of transmission and turns off the tap for TB. To help focus efforts, policies, and funding on that, Guy Marks from the International Union Against Tuberculosis and Lung Disease, is busting five harmful misconceptions.

Opinion: Myth busting 5 tuberculosis misconceptions on World TB Day

Opinion: Myth busting 5 tuberculosis misconceptions on World TB Day


By Guy Marks

Active case-finding breaks the chain of transmission and turns off the tap for TB. To help focus efforts, policies, and funding on that, Guy Marks from the International Union Against Tuberculosis and Lung Disease, is busting five harmful misconceptions.

Is tuberculosis being left out of climate-health debate?

Is tuberculosis being left out of climate-health debate?


By Jenny Lei Ravelo

Unlike diseases such as malaria and dengue, the links between climate change and TB aren’t as direct. But the impact of climate change on issues such as displacement and malnutrition can have serious consequences for TB, according to experts.

Opinion: How beating TB today better prepares us for pandemics tomorrow

Opinion: How beating TB today better prepares us for pandemics tomorrow


By Janika Hauser, Madhukar Pai

There is a series of opportunities for dual impact in the fight against tuberculosis and the effort to prepare for future pandemics. Three, in particular, warrant closer consideration.

DevExplains: How NGOs can access Global Fund grants

DevExplains: How NGOs can access Global Fund grants


By Jenny Lei Ravelo

The Global Fund hopes to send country allocation letters before the year ends, which kicks off the whole funding request process.

The Global Fund’s top 10 implementing partners

The Global Fund’s top 10 implementing partners


By Miguel Antonio Tamonan

The Global Fund has invested over $50 billion in more than 100 countries in the last two decades. We looked into the data to see where the money is going and who are implementing the grants.

Global Fund pledge: ‘It’s not too late to take action,’ NGOs urge UK

Global Fund pledge: ‘It’s not too late to take action,’ NGOs urge UK


By Jenny Lei Ravelo

In two weeks, the board of the Global Fund to Fight AIDS, Tuberculosis and Malaria will be meeting to decide how much total grant funding will be made available to countries in the next three years, without additional pledges from big donors such as the U.K.

$250B plan to end TB seeks new vaccine by 2025

$250B plan to end TB seeks new vaccine by 2025


By Jenny Lei Ravelo

The plan requires $250 billion in funding from now through 2030 — a significant challenge for a disease that has been chronically underfunded.

Opinion: Why Canada needs to step up Global Fund support this year

Opinion: Why Canada needs to step up Global Fund support this year


By Leigh Raithby

The Global Fund has asked donors to increase their contributions by 30% over 2019 levels due to the devastating impact of COVID-19 on health services. Advocates around the world are looking to Canada to set this precedent.

New agreements cut price for short-course TB treatments to under $20

New agreements cut price for short-course TB treatments to under $20


By Jenny Lei Ravelo

Short-course rifapentine-based TB regimens help patients complete their preventive treatment, compared to taking multiple pills daily for six months. Health organizations hope the reduced pricing will lead more countries to roll out the shorter regimen.

What do you think about this series on TB?


#TalkingTB

#DevexSeries

TB Knowledge Hub

Produced by

Devex

Devex

Devex is the media platform for the global development community. A social enterprise, we connect and inform over one million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people.

In Partnership with

Stop TB Partnership

Stop TB Partnership

The Stop TB Partnership brings together expertise from a broad spectrum of country, regional, and global partners in our shared mission to revolutionize the TB space and end TB by 2030.